• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance

    2/14/24 8:00:00 AM ET
    $YS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $YS alert in real time by email

    GAITHERSBURG, Md., Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that the Company received a requisition to convene an extraordinary general meeting ("EGM") of the Company (the "Requisition") from APEX Prospect Limited (the "Requisitioning Shareholder"), a registered member of the Company that holds no less than 10% of the aggregate voting power of the Company's share capital as of February 12, 2024.

    (PRNewsfoto/YishengBio Co., Ltd)

    In the Requisition, the proposed meeting agenda for the EGM includes: (i) to reaffirm the appointment of each of Haitao Zhao, Henry Chen, Pierson Yue Pan, Yuntao Cui, Jin Wang, Chunyuan (Brenda) Wu as a member of the Board of Directors of the Company (the "Board"); (ii) to conduct an independent investigation of any alleged misconduct and/or illegal activities of the Company caused by or under the control of Mr. Yi Zhang, the former chairperson of the Board; (iii) to take immediate actions to strengthen the Company's corporate governance and internal control and management as advised by counsel and other professionals; and (iv) to remove Mr. Yi Zhang from all positions with the Company and any subsidiaries of the Company, including without limitation as director, officer and/or legal representative.

    The Board had reviewed the Requisition and decided to convene an EGM (the "Proposed EGM") at 35th Floor, Two Exchange Square, 8 Connaught Place Central, Hong Kong on February 22, 2024 at 9:00 a.m. (Hong Kong time). The Board resolved to convene the Proposed EGM to consider and vote on the resolutions proposed by the Requisitioning Shareholder. A copy of the notice of the Proposed EGM posted to the Company's website, a form of the voting proxy for the Proposed EGM and a copy of the Requisition is attached as Exhibit 99.2, Exhibit 99.3 and Exhibit 99.4, respectively, to the Current Report on Form 6-K furnished by the Company with the United States Securities and Exchange Commission today. If you wish to virtually attend the Proposed EGM, you are encouraged to contact the Company via email at [email protected].

    About YS Biopharma

    YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry. For more information, please visit investor.ysbiopharm.com.

    Cautionary Statement Regarding Forward-Looking Statements

    This press release contains "forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of the Company, the development progress of all product candidates, the progress and results of all clinical trials, the Company's ability to source and retain talent, and the cash position of the Company following the closing of the Business Combination. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of YS Biopharma's management and are not predictions of actual performance.

    These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although YS Biopharma believes that it has a reasonable basis for each forward-looking statement contained in this press release, YS Biopharma cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. In addition, there are risks and uncertainties described in the documents filed by YS Biopharma from time to time with the U.S. Securities and Exchange Commission ("SEC"). These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

    YS Biopharma cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, the outcome of any potential litigation, government or regulatory proceedings, the sales performance of the marketed vaccine product and the clinical trial development results of the product candidates of YS Biopharma, and other risks and uncertainties, including those included under the heading "Risk Factors" in the post-effective amendment No. 2 to Form F-1 filed with the SEC on January 23, 2024 which became effective on January 25, 2024, and other filings with the SEC. There may be additional risks that YS Biopharma does not presently know or that YS Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of YS Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while YS Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of YS Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, YS Biopharma does not undertake any duty to update these forward-looking statements.

    Investor Relations Contact

    Robin Yang

    Partner, ICR, LLC

    Tel: +1 (212) 537-4035

    Email: [email protected]

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-to-hold-an-extraordinary-general-meeting-on-february-22-2024-pursuant-to-a-shareholder-requisition-to-enhance-corporate-governance-302061800.html

    SOURCE YS Biopharma Co., Ltd.

    Get the next $YS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $YS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $YS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan

      GAITHERSBURG, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma Co., Ltd (NASDAQ:LSB) ("LakeShore Biopharma" or the "Company"), a global leader in the discovery, development, manufacturing, and delivery of next-generation vaccines and therapeutic biologics for infectious diseases and cancer, today announced the initiation of its Biologics License Application (BLA) submission to the Drug Regulatory Authority of Pakistan (DRAP) for the conditional approval of its PIKA rabies vaccine for post-exposure prophylaxis. This submission is based on the results that met the primary endpoints of the vaccine's global pivotal trial and demonstrated the vaccine's potential to achieve accelerated

      11/7/24 8:00:00 AM ET
      $LSB
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • YS Biopharma Announces Name Change to LakeShore Biopharma

      GAITHERSBURG, Md., May 24, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced it is changing its legal name from "YS Biopharma Co., Ltd." to "LakeShore Biopharma Co., Ltd". Dr. David Shao, Director, President, Co-Chief Executive Officer, and Chief Business Officer of the Company, commented, "We have decided to change our company nam

      5/24/24 7:30:00 AM ET
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • YS Biopharma Announces Results of Extraordinary General Meeting

      GAITHERSBURG, Md., May 21, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on May 21, 2024 in Hong Kong. Each of the following resolutions was passed at the EGM: As a special resolution that, the name of the Company be and hereby is changed from YS Biopharma Co., L

      5/21/24 4:15:00 PM ET
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YS
    Leadership Updates

    Live Leadership Updates

    See more
    • YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer

      GAITHERSBURG, Md., May 7, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will hold an Extraordinary General Meeting of the Company (the "EGM") at the 35th Floor, Two Exchange Square, 8 Connaught Place, Central, Hong Kong, at 9:00 a.m. on May 21, 2024 (Hong Kong time), with an option for Zoom dial-in. The close of busines

      5/7/24 4:20:00 PM ET
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024

      GAITHERSBURG, Md., Feb. 22, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the results of its extraordinary general meeting (the "EGM") held on February 22, 2024 in Hong Kong. The Company's shareholders voted in favor of each of the following resolutions: Resolution 1 : as an ordinary resolution, that the appointment of each o

      2/22/24 5:00:00 PM ET
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.

      NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Yi Zhang and shareholders representing over 59.2% of the outstanding shares of YS Biopharma Co., Ltd. (the "Company" or "YS") (NASDAQ:YS) (the "Convening Shareholders") today announced the successful approval of all resolutions at the YS Extraordinary General Meeting of Shareholders ("EGM") held today. 62,132,308 shares out of 93,058,197 total outstanding shares of YS voted in the EGM, which represents 66.8% of all outstanding shares. Before the EGM, individuals purporting to be representatives of the Company arrived at the offices where the EGM was to be conducted, but they indicated that they intended to disrupt the business for which the EGM was con

      2/16/24 5:36:00 PM ET
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YS
    SEC Filings

    See more
    • SEC Form 6-K filed by YS Biopharma Co. Ltd.

      6-K - YS Biopharma Co., Ltd. (0001946399) (Filer)

      5/24/24 7:45:05 AM ET
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by YS Biopharma Co. Ltd.

      6-K - YS Biopharma Co., Ltd. (0001946399) (Filer)

      5/21/24 4:30:08 PM ET
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by YS Biopharma Co. Ltd.

      S-8 - YS Biopharma Co., Ltd. (0001946399) (Filer)

      5/20/24 4:16:31 PM ET
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $YS
    Financials

    Live finance-specific insights

    See more
    • YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024

      GAITHERSBURG, Md., April 19, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its unaudited consolidated financial results for the first nine months of the fiscal year ended March 31, 2024. Dr. David Shao, Director, President, and CEO of the Company, commented, "During the first nine months of fiscal year 2024, our topline continu

      4/19/24 7:00:00 AM ET
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • YS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024

      GAITHERSBURG, Md., April 16, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it plans to release its financial results for the first nine months of the fiscal year ended March 31, 2024, before the U.S. market opens on Friday, April 19, 2024. The Company's management will hold an earnings conference call at 8:00 A.M. Eastern

      4/16/24 8:00:00 AM ET
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024

      Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues Gross margin increases to 80.3%; balance sheet remains strong GAITHERSBURG, Md., Aug. 15, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its unaudited financial results for the first quarter of the fiscal year ended March 31, 2024 (the "first quarter of fiscal year 2024").

      8/15/23 5:00:00 PM ET
      $YS
      Biotechnology: Pharmaceutical Preparations
      Health Care